Maddalena Marasa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maddalena Marasa has a total of 590 co-authors. Here are the top co-authors by number of shared publications:
- Ali G. Gharavi
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA
15 shared publications - Pietro A. Canetta
Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York
11 shared publications Isabella Pisani
Nephrology Unit, Parma University Hospital, Parma, Italy
9 shared publicationsKrzysztof Kiryluk
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA
9 shared publicationsLoreto Gesualdo
Division of Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy
9 shared publicationsTze Y. Lim
Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, USA
9 shared publications
Latest Publications
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1981-1994
Primary Glomerular Diseases in the Elderly
Key Points: Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases. Background: Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical–histologic presentation, treatment, and outcome of PGDs. Methods: Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18–39 years), middle-aged adults (40–64 years), and elderly patients (≥65 years). Clinical–histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine–Gray models were fitted to evaluate the impact of age on the composite kidney outcome. Results: Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34–75] versus 84 [50–115] in young adults and 65 [43–91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features—particularly arteriosclerosis—increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%–14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65–0.79). Conclusions: Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1981-1994
Primary Glomerular Diseases in the Elderly
Key Points: Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases. Background: Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical–histologic presentation, treatment, and outcome of PGDs. Methods: Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18–39 years), middle-aged adults (40–64 years), and elderly patients (≥65 years). Clinical–histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine–Gray models were fitted to evaluate the impact of age on the composite kidney outcome. Results: Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34–75] versus 84 [50–115] in young adults and 65 [43–91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features—particularly arteriosclerosis—increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%–14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65–0.79). Conclusions: Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.
- 23 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 626-640
Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN
Key Points: This retrospective study analyzed clinical, histological, and biochemical data from a large cohort of participants with biopsy-proven primary C3 glomerulopathy/immune complex-mediated membranoproliferative GN. C3 glomerulopathy and immune complex-mediated membranoproliferative GN subjects shared most baseline and longitudinal features; 10-year kidney survival did not differ across histological subtypes. Older age at onset and higher proteinuria levels at 1 year from biopsy were the strongest predictors of kidney failure. Background: Membranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall prognosis is poor and the treatment options remain limited. Outcome predictors and reliable surrogate endpoints are critically needed for interventional trials. Herein, we described the natural history and analyzed clinical, histological and biochemical data from a large cohort of patients with primary C3G/IC-MPGN. Methods: This is a retrospective analysis of patients with biopsy-proven primary C3G or IC-MPGN from the Italian Registry of MPGN. Demographic, clinical and histopathological data, molecular complement profiles, treatment patterns, and outcomes were collected. We performed univariable and multivariable Cox regressions and Kaplan–Meier survival analyses to assess risk associations with kidney disease progression. The composite endpoint included ESKD (defined by either eGFR 2 , initiation of chronic dialysis or kidney transplantation), doubling of serum creatinine at the last available follow-up, or death by kidney-related causes. Results: Of the 349 patients identified, 208 had C3G and 141 IC-MPGN. Females were 41%, and over half were younger than 18 years old at time of biopsy. C3G and IC-MPGN patients shared most baseline and longitudinal features, with IC-MPGN patients presenting with higher baseline proteinuria (median 4.0 versus 2.3 g/24 hours, P < 0.001). Median eGFR at presentation was 83 ml/min per 1.73 m 2 . Twenty-six percent of patients progressed to ESKD over a median follow-up of 5 years from diagnosis. Higher proteinuria levels at 1 year from biopsy, particularly ≥1 g/24 hours, were significantly associated with a higher risk of adverse kidney outcomes. Pediatric onset was associated with better kidney survival, whereas kidney survival at 10 years did not statistically differ across histological subtypes. Complement dysregulation and rare functional variants in complement genes were not associated with outcomes. Conclusions: Our findings from a large and well-characterized cohort of individuals with primary C3G/IC-MPGN identify age at onset and proteinuria levels as associations with kidney survival, a finding that should inform future interventional trials.
- 23 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 626-640
Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN
Key Points: This retrospective study analyzed clinical, histological, and biochemical data from a large cohort of participants with biopsy-proven primary C3 glomerulopathy/immune complex-mediated membranoproliferative GN. C3 glomerulopathy and immune complex-mediated membranoproliferative GN subjects shared most baseline and longitudinal features; 10-year kidney survival did not differ across histological subtypes. Older age at onset and higher proteinuria levels at 1 year from biopsy were the strongest predictors of kidney failure. Background: Membranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall prognosis is poor and the treatment options remain limited. Outcome predictors and reliable surrogate endpoints are critically needed for interventional trials. Herein, we described the natural history and analyzed clinical, histological and biochemical data from a large cohort of patients with primary C3G/IC-MPGN. Methods: This is a retrospective analysis of patients with biopsy-proven primary C3G or IC-MPGN from the Italian Registry of MPGN. Demographic, clinical and histopathological data, molecular complement profiles, treatment patterns, and outcomes were collected. We performed univariable and multivariable Cox regressions and Kaplan–Meier survival analyses to assess risk associations with kidney disease progression. The composite endpoint included ESKD (defined by either eGFR 2 , initiation of chronic dialysis or kidney transplantation), doubling of serum creatinine at the last available follow-up, or death by kidney-related causes. Results: Of the 349 patients identified, 208 had C3G and 141 IC-MPGN. Females were 41%, and over half were younger than 18 years old at time of biopsy. C3G and IC-MPGN patients shared most baseline and longitudinal features, with IC-MPGN patients presenting with higher baseline proteinuria (median 4.0 versus 2.3 g/24 hours, P < 0.001). Median eGFR at presentation was 83 ml/min per 1.73 m 2 . Twenty-six percent of patients progressed to ESKD over a median follow-up of 5 years from diagnosis. Higher proteinuria levels at 1 year from biopsy, particularly ≥1 g/24 hours, were significantly associated with a higher risk of adverse kidney outcomes. Pediatric onset was associated with better kidney survival, whereas kidney survival at 10 years did not statistically differ across histological subtypes. Complement dysregulation and rare functional variants in complement genes were not associated with outcomes. Conclusions: Our findings from a large and well-characterized cohort of individuals with primary C3G/IC-MPGN identify age at onset and proteinuria levels as associations with kidney survival, a finding that should inform future interventional trials.
- Open Access
- 10 October 2025
- Published by Elsevier in Kidney International
- Vol. 109 (1) , 178-195
Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy
- 10 October 2025
- Published by Elsevier in Kidney International
- Vol. 109 (1) , 178-195
Open AccessHierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy
- Open Access
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes
- Open Access
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Exome analysis links kidney malformations to developmental disorders and reveals causal genes
Congenital anomalies of the kidneys and urinary tract (CAKUT) are developmental disorders that commonly cause pediatric chronic kidney disease and mortality. We examine here rare coding variants in 248 CAKUT trios and 1742 singleton CAKUT cases and compare them to 22,258 controls. Diagnostic and candidate diagnostic variants are detected in 14.1% of cases. We find a significant enrichment of rare damaging variants in constrained genes expressed during kidney development and in genes associated with other developmental disorders, suggesting phenotype expansion. Consistent with these data, 18% of CAKUT patients with diagnostic variants have neurodevelopmental or cardiac phenotypes. We identify 40 candidate genes, including CELSR1, SSBP2, XPO1, NR6A1, and ARID3A. Two are confirmed as CAKUT genes: ARID3A and NR6A1. This study suggests that many yet-unidentified syndromes would be discoverable with larger cohorts and cross-phenotype analysis, leading to clarification of the genetic and phenotypic spectrum of developmental disorders.
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessExome analysis links kidney malformations to developmental disorders and reveals causal genes
Congenital anomalies of the kidneys and urinary tract (CAKUT) are developmental disorders that commonly cause pediatric chronic kidney disease and mortality. We examine here rare coding variants in 248 CAKUT trios and 1742 singleton CAKUT cases and compare them to 22,258 controls. Diagnostic and candidate diagnostic variants are detected in 14.1% of cases. We find a significant enrichment of rare damaging variants in constrained genes expressed during kidney development and in genes associated with other developmental disorders, suggesting phenotype expansion. Consistent with these data, 18% of CAKUT patients with diagnostic variants have neurodevelopmental or cardiac phenotypes. We identify 40 candidate genes, including CELSR1, SSBP2, XPO1, NR6A1, and ARID3A. Two are confirmed as CAKUT genes: ARID3A and NR6A1. This study suggests that many yet-unidentified syndromes would be discoverable with larger cohorts and cross-phenotype analysis, leading to clarification of the genetic and phenotypic spectrum of developmental disorders.
- 11 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1561-1571
Family History in the Context of CKD
Key Points: Family history of kidney disease was not associated with kidney disease progression in the context of established CKD. Family history of diabetes was a risk factor of CKD progression independently of diabetes status, polygenic risk, and traditional risk factors. Background: A family history of health conditions may reflect shared genetic and/or environmental risk. It is not well known to what extent family history affects outcomes among patients with CKD. In this study, we investigated the associations of family history of CKD, diabetes, and other conditions with common comorbidities and kidney disease progression among patients with CKD. Methods: We performed an observational study of two prospective CKD cohorts, 2573 adults and children from the Cure Glomerulopathy Network and 3939 Chronic Renal Insufficiency Cohort adult participants. Self-reported first-degree family history of CKD, diabetes, and other common diseases was tested for associations with the risk of comorbidities and CKD progression using multivariable models. Results: Family history of common comorbid conditions was associated with higher risk of these conditions in the context of CKD, including approximately by over three-fold for diabetes (adjusted odds ratio [OR], 3.37; 95% confidence interval [CI], 2.73 to 4.15), 48% for cancer (adjusted OR, 1.48; 95% CI, 1.05 to 2.09), and 69% for cardiovascular disease (adjusted OR, 1.69; 95% CI, 1.36 to 2.10 in combined cohorts). While polygenic risk score (PRS) for CKD was associated with kidney disease progression (adjusted hazards ratio, 1.11; 95% CI, 1.06 to 1.16 in combined cohorts), family history of kidney disease was not an independent risk factor of disease progression in the context of existing CKD. By contrast, family history of diabetes was significantly associated with a higher risk of CKD progression independently of diabetes occurrence or PRS for diabetes (adjusted hazards ratio, 1.19; 95% CI, 1.05 to 1.35 in combined cohorts). Conclusions: Broad collection of family history in the context of CKD improved clinical risk stratification. Family history of diabetes was consistently associated with a higher risk of CKD progression independently of diabetes status or PRS for diabetes in both cohorts.
- 11 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1561-1571
Family History in the Context of CKD
Key Points: Family history of kidney disease was not associated with kidney disease progression in the context of established CKD. Family history of diabetes was a risk factor of CKD progression independently of diabetes status, polygenic risk, and traditional risk factors. Background: A family history of health conditions may reflect shared genetic and/or environmental risk. It is not well known to what extent family history affects outcomes among patients with CKD. In this study, we investigated the associations of family history of CKD, diabetes, and other conditions with common comorbidities and kidney disease progression among patients with CKD. Methods: We performed an observational study of two prospective CKD cohorts, 2573 adults and children from the Cure Glomerulopathy Network and 3939 Chronic Renal Insufficiency Cohort adult participants. Self-reported first-degree family history of CKD, diabetes, and other common diseases was tested for associations with the risk of comorbidities and CKD progression using multivariable models. Results: Family history of common comorbid conditions was associated with higher risk of these conditions in the context of CKD, including approximately by over three-fold for diabetes (adjusted odds ratio [OR], 3.37; 95% confidence interval [CI], 2.73 to 4.15), 48% for cancer (adjusted OR, 1.48; 95% CI, 1.05 to 2.09), and 69% for cardiovascular disease (adjusted OR, 1.69; 95% CI, 1.36 to 2.10 in combined cohorts). While polygenic risk score (PRS) for CKD was associated with kidney disease progression (adjusted hazards ratio, 1.11; 95% CI, 1.06 to 1.16 in combined cohorts), family history of kidney disease was not an independent risk factor of disease progression in the context of existing CKD. By contrast, family history of diabetes was significantly associated with a higher risk of CKD progression independently of diabetes occurrence or PRS for diabetes (adjusted hazards ratio, 1.19; 95% CI, 1.05 to 1.35 in combined cohorts). Conclusions: Broad collection of family history in the context of CKD improved clinical risk stratification. Family history of diabetes was consistently associated with a higher risk of CKD progression independently of diabetes status or PRS for diabetes in both cohorts.
- 9 October 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 40 (3) , 755-763
Pediatric nephrologists’ perspectives and clinical practices related to genetic testing and education
Background While genetic testing is now more accessible in pediatric nephrology, little is known about the views of pediatric nephrologists regarding genetic testing in clinical settings. Methods An online 41-item survey was developed and distributed via professional listservs to self-identified U.S. licensed pediatric nephrologists from January 22 to May 4, 2021. Results Pediatric nephrologists had a high referral rate to genetic counseling and agreed on the significant impact of genetic testing on diagnosis, treatment, prognosis, counseling, and kidney transplant planning. Challenges for the utilization of genetic testing among pediatric nephrologists include the need to (1) learn how to counsel patients on the risks and benefits of genetic testing, (2) choose appropriate testing, (3) interpret genetic results, and (4) return those results to patients and families. Conclusion There exists an opportunity to expand genetic testing education for pediatric nephrologists to assist incorporation of genetic testing into clinical practice. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 9 October 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 40 (3) , 755-763
Pediatric nephrologists’ perspectives and clinical practices related to genetic testing and education
Background While genetic testing is now more accessible in pediatric nephrology, little is known about the views of pediatric nephrologists regarding genetic testing in clinical settings. Methods An online 41-item survey was developed and distributed via professional listservs to self-identified U.S. licensed pediatric nephrologists from January 22 to May 4, 2021. Results Pediatric nephrologists had a high referral rate to genetic counseling and agreed on the significant impact of genetic testing on diagnosis, treatment, prognosis, counseling, and kidney transplant planning. Challenges for the utilization of genetic testing among pediatric nephrologists include the need to (1) learn how to counsel patients on the risks and benefits of genetic testing, (2) choose appropriate testing, (3) interpret genetic results, and (4) return those results to patients and families. Conclusion There exists an opportunity to expand genetic testing education for pediatric nephrologists to assist incorporation of genetic testing into clinical practice. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
- 2 September 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (11) , 3278-3289
Nephrologists’ Views on a Workflow for Returning Genetic Results to Research Participants
- 2 September 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (11) , 3278-3289
Open AccessNephrologists’ Views on a Workflow for Returning Genetic Results to Research Participants
- Open Access
- 30 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-8
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
African Americans have a significantly higher risk of developing chronic kidney disease, especially focal segmental glomerulosclerosis -, than European Americans. Two coding variants (G1 and G2) in the APOL1 gene play a major role in this disparity. While 13% of African Americans carry the high-risk recessive genotypes, only a fraction of these individuals develops FSGS or kidney failure, indicating the involvement of additional disease modifiers. Here, we show that the presence of the APOL1 p.N264K missense variant, when co-inherited with the G2 APOL1 risk allele, substantially reduces the penetrance of the G1G2 and G2G2 high-risk genotypes by rendering these genotypes low-risk. These results align with prior functional evidence showing that the p.N264K variant reduces the toxicity of the APOL1 high-risk alleles. These findings have important implications for our understanding of the mechanisms of APOL1-associated nephropathy, as well as for the clinical management of individuals with high-risk genotypes that include the G2 allele.
- 30 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-8
Open AccessStrong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
African Americans have a significantly higher risk of developing chronic kidney disease, especially focal segmental glomerulosclerosis -, than European Americans. Two coding variants (G1 and G2) in the APOL1 gene play a major role in this disparity. While 13% of African Americans carry the high-risk recessive genotypes, only a fraction of these individuals develops FSGS or kidney failure, indicating the involvement of additional disease modifiers. Here, we show that the presence of the APOL1 p.N264K missense variant, when co-inherited with the G2 APOL1 risk allele, substantially reduces the penetrance of the G1G2 and G2G2 high-risk genotypes by rendering these genotypes low-risk. These results align with prior functional evidence showing that the p.N264K variant reduces the toxicity of the APOL1 high-risk alleles. These findings have important implications for our understanding of the mechanisms of APOL1-associated nephropathy, as well as for the clinical management of individuals with high-risk genotypes that include the G2 allele.
- Top Cited PapersOpen Access
- 5 October 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (12) , 2039-2050
The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease
Significance Statement: Accurate diagnosis of a patient's underlying cause of CKD can influence management and ultimately overall health. The single-arm, interventional, prospective Renasight Clinical Application, Review, and Evaluation study assessed the utility of genetic testing with a 385 gene kidney disease panel on the diagnosis and management of 1623 patients with CKD. Among 20.8% of patients who had positive genetic findings, half resulted in a new or reclassified diagnosis. In addition, a change in management because of genetic testing was reported for 90.7% of patients with positive findings, including treatment changes in 32.9%. These findings demonstrate that genetic testing has a significant effect on both CKD diagnosis and management. Background: Genetic testing in CKD has recently been shown to have diagnostic utility with many predicted implications for clinical management, but its effect on management has not been prospectively evaluated. Methods: Renasight Clinical Application, Review, and Evaluation RenaCARE (ClinicalTrials.gov NCT05846113) is a single-arm, interventional, prospective, multicenter study that evaluated the utility of genetic testing with a broad, 385 gene panel (the Renasight TM test) on the diagnosis and management of adult patients with CKD recruited from 31 US-based community and academic medical centers. Patient medical history and clinical CKD diagnosis were collected at enrollment. Physician responses to questionnaires regarding patient disease categorization and management were collected before genetic testing and 1 month after the return of test results. Changes in CKD diagnosis and management after genetic testing were assessed. Results: Of 1623 patients with CKD in 13 predefined clinical disease categories (ages, 18–96; median, 55 years), 20.8% ( n =338) had positive genetic findings spanning 54 genes. Positive genetic findings provided a new diagnosis or reclassified a prior diagnosis in 48.8% of those patients. Physicians reported that genetic results altered the management of 90.7% of patients with a positive genetic finding, including changes in treatment plan, which were reported in 32.9% of these patients. Conclusions: Genetic testing with a CKD-focused 385 gene panel substantially refined clinical diagnoses and had widespread implications for clinical management, including appropriate treatment strategies. These data support the utility of broader integration of panels of genetic tests into the clinical care paradigm for patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.
- 5 October 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (12) , 2039-2050
Top Cited PapersOpen AccessThe Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease
Significance Statement: Accurate diagnosis of a patient's underlying cause of CKD can influence management and ultimately overall health. The single-arm, interventional, prospective Renasight Clinical Application, Review, and Evaluation study assessed the utility of genetic testing with a 385 gene kidney disease panel on the diagnosis and management of 1623 patients with CKD. Among 20.8% of patients who had positive genetic findings, half resulted in a new or reclassified diagnosis. In addition, a change in management because of genetic testing was reported for 90.7% of patients with positive findings, including treatment changes in 32.9%. These findings demonstrate that genetic testing has a significant effect on both CKD diagnosis and management. Background: Genetic testing in CKD has recently been shown to have diagnostic utility with many predicted implications for clinical management, but its effect on management has not been prospectively evaluated. Methods: Renasight Clinical Application, Review, and Evaluation RenaCARE (ClinicalTrials.gov NCT05846113) is a single-arm, interventional, prospective, multicenter study that evaluated the utility of genetic testing with a broad, 385 gene panel (the Renasight TM test) on the diagnosis and management of adult patients with CKD recruited from 31 US-based community and academic medical centers. Patient medical history and clinical CKD diagnosis were collected at enrollment. Physician responses to questionnaires regarding patient disease categorization and management were collected before genetic testing and 1 month after the return of test results. Changes in CKD diagnosis and management after genetic testing were assessed. Results: Of 1623 patients with CKD in 13 predefined clinical disease categories (ages, 18–96; median, 55 years), 20.8% ( n =338) had positive genetic findings spanning 54 genes. Positive genetic findings provided a new diagnosis or reclassified a prior diagnosis in 48.8% of those patients. Physicians reported that genetic results altered the management of 90.7% of patients with a positive genetic finding, including changes in treatment plan, which were reported in 32.9% of these patients. Conclusions: Genetic testing with a CKD-focused 385 gene panel substantially refined clinical diagnoses and had widespread implications for clinical management, including appropriate treatment strategies. These data support the utility of broader integration of panels of genetic tests into the clinical care paradigm for patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.